Logo

Novo Nordisk Reports Results of Refixia (nonacog beta pegol) in Two P-III Studies for Hemophilia B in Children

Share this

Novo Nordisk Reports Results of Refixia (nonacog beta pegol) in Two P-III Studies for Hemophilia B in Children

Shots:

  • The two P-III studies include Paradigm5 & 6. Paradigm5 involves assessing of Refixia (40 IU/kg- qw) in 25 children with hemophilia B aged ≤12 yrs. resulted in low bleeding rates with 20% bleed free patients and 64% with no spontaneous bleeds. No children developed inhibitory Ab & no new safety signals are observed
  • The P-III Paradigm6 study involves assessing of Refixia in male with FIX ≤2%- prior untreated/with ≤3 EDs to FIX-containing products aged <6 yrs. resulted in low bleeding rates and good bleed resolution with median ABRs of 0.0 for overall- spontaneous and traumatic bleeds + 6.1% patients developed inhibitory Ab
  • Refixia (N9-GP) is an extended half-life factor IX molecule for replacement therapy indicated to treat and prevent bleeding in patients with haemophilia B and has received EMA’s approval in Jun’2017

Click here to read full press release/ article | Ref: Novo Nordisk | Image: Novo Nordisk


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions